Immune thrombocytopenia (ITP) - management
ITP mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Immune-mediated platelet destruction and impaired production, a diagnosis of exclusion. Treatment is guided by bleeding and platelet count rather than number alone, with corticosteroids first line and thrombopoietin receptor agonists prominent in second line.
Red flags
- Intracranial or major GI bleeding
- Platelets <10-20 x10^9/L with wet purpura/mucosal bleeding
- New neurological symptoms
- Coexisting anaemia from blood loss or haemolysis
- Pregnancy with severe thrombocytopenia
Assessment
Differential diagnosis
- Drug-induced thrombocytopenia
- Thrombotic microangiopathy (TTP/HUS)
- Marrow infiltration/failure
- Hypersplenism
- Pseudothrombocytopenia (EDTA)
- Secondary ITP (SLE, HIV, HCV, CLL, H. pylori)
Investigations
- FBC and blood film (isolated thrombocytopenia, exclude clumping/schistocytes)
- Review medications and recent infection
- HIV, hepatitis C, H. pylori testing
- Immunoglobulins and autoimmune screen where indicated
- Direct antiglobulin test if anaemia (Evans)
- Bone marrow only if atypical features or age/treatment-refractory
Management
- Confirm isolated thrombocytopenia and exclude secondary causes and pseudothrombocytopenia
- Base treatment decisions on bleeding and risk, not the platelet number alone
- Observe without treatment if platelets are adequate (often >30 x10^9/L) and no bleeding
- Start corticosteroids first line - prednisolone taper or short high-dose dexamethasone pulses
- Add IV immunoglobulin for severe bleeding or when a rapid rise is needed (e.g. before surgery)
- Give platelet transfusion only for life-threatening bleeding, alongside IVIg/steroids
- For steroid-dependent or relapsing disease move to second line: thrombopoietin receptor agonists or rituximab
- Consider fostamatinib or splenectomy in refractory cases
- Treat secondary causes (eradicate H. pylori, treat HIV/HCV)
- Provide thrombosis awareness (TPO-RAs and recovery raise VTE risk) and monitor counts
Drugs & doses
Prednisolone 1 mg/kg PO daily (max 80 mg) then taper
Dexamethasone 40 mg PO once daily for 4 days (pulsed, repeatable)
IV immunoglobulin 1 g/kg IV, repeat at 48 h if needed
Eltrombopag 50 mg PO once daily (25 mg in East Asian patients), titrate to response
Romiplostim 1 mcg/kg SC weekly, titrate to max 10 mcg/kg; rituximab 375 mg/m2 IV weekly x4
Disposition
Outpatient haematology for stable disease; admit for bleeding or very low counts; emergency management for intracranial haemorrhage.
Complications & pitfalls
- Life-threatening haemorrhage (uncommon, mainly very low counts)
- Steroid toxicity and dependence
- Thrombosis with TPO-RAs and on recovery
- Chronic relapsing disease
- Post-splenectomy infection risk
Exam pearls
- Treat the patient's bleeding, not the platelet count
- Platelet transfusions are reserved for life-threatening bleeding (rapidly consumed otherwise)
- Pulsed dexamethasone gives durable responses with fewer cumulative steroid effects
- TPO-RAs and clinical recovery both increase thrombotic risk
- Always screen for HIV, HCV and H. pylori
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.